CSO Keiichi Nakayama to Speak at AMED Seeds Acceleration Pitch during JHVS 2026

Anti-Cancer Technologies Inc. is pleased to announce that founder and CSO Keiichi Nakayama will be presenting at the "4th AMED Seeds Acceleration Pitch," organized by the Japan Agency for Medical Research and Development (AMED), as part of Japan Healthcare Venture Summit (JHVS) 2026. The event will take place on Wednesday, October 7, 2026, at PACIFICO Yokohama.The pitch event aims to introduce promising drug discovery seeds supported by AMED to facilitate strategic partnering and matching with AMED-certified venture capital firms, pharmaceutical companies, and financial institutions. During the session, Dr. Nakayama will present our research and development pipeline under the title: "Research and Development of Novel Metabolic Inhibitors to Eradicate Intractable Cancers."Through this presentation, Anti-Cancer Technologies Inc. seeks to raise international awareness of its innovative therapeutic research among investors and biopharmaceutical partners, driving forward collaborative opportunities for future R&D and commercialization.